In summary, decreased levels of PPARg and adiponectin in PAH patients is being pointed out as an important mechanism for the worsening of PAH, which needs to be further explored as a target for PAH treatment. This evidence concerns the gene ADIPOQ and pulmonary arterial hypertension.